Tyrosine News and Research

RSS

Researchers study prevalence of SARS-CoV-2 UK variant at University of Texas

Researchers at the University of Texas at Austin and Santa Fe Institute in the US used quantitative polymerase chain reaction (PCR) data from a surveillance testing program on a large university campus to estimate how fast the new variant spreads. The team used the data to provide local situational information on the COVID-19 pandemic.

10 Mar 2021

New compound can reduce overactivation without impairing the body's immunity response

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

10 Mar 2021

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

Researchers at Erasmus University Medical Center in The Netherlands have explored how and why new variants of SARS-CoV-2 have exhibited heightened infectivity.

24 Feb 2021

New insights on structural biology may help design more efficient antibodies

In structural biology, some molecules are so unusual they can only be captured with a unique set of tools.

18 Feb 2021

Researchers unlock mysteries of protein that plays key regulatory role in cancer therapies

Researchers from the University of Virginia, Lehigh University, and the Massachusetts Institute of Technology are pooling their respective labs' expertise to unlock the mysteries of a protein that plays a critical regulatory role in human health and disease. Knowing how the protein works could lead to improved therapies for cancers and other diseases.

5 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Study discovers promising therapeutic agent to inhibit melanoma progression

There have been great advances in treating melanoma over the past five years, however, even with these treatments many patients quickly develop drug resistance and die from their disease.

1 Feb 2021

Drug intervention may prevent heart damage caused by chemotherapy

There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.

26 Jan 2021

New UK SARS-CoV-2 variant circulating in US since November, says study

A new study by researchers at the Department of Ecology and Evolutionary Biology, University of Arizona, showed that the new variant has circulated in the US since November.

26 Jan 2021

Combination therapy shows potential for treating lung cancer

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.

22 Jan 2021

How have new SARS-CoV-2 strains become more transmissible?

A new study discusses the effect of specific mutations on the sensitivity of SARS-CoV-2's spike protein to elastase, and on the intramolecular conformational changes.

22 Jan 2021

Study: NTRK fusions are far more frequently seen in pediatric tumors

In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors.

16 Jan 2021

New drug reduces tumor volume and pain in patients with neurofibromatosis type 1

Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).

15 Jan 2021

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.

13 Jan 2021

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.

13 Jan 2021

New taxonomic classification of non-skeletal rare congenital disorders with impact on bone physiology

Thanks to major progress in the understanding and management of rare congenital diseases and syndromes, many patients with these rare disorders are now living longer lives.

13 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Tyrosine News and Research

Researchers study prevalence of SARS-CoV-2 UK variant at University of Texas

New compound can reduce overactivation without impairing the body's immunity response

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

New insights on structural biology may help design more efficient antibodies

Researchers unlock mysteries of protein that plays key regulatory role in cancer therapies

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Study discovers promising therapeutic agent to inhibit melanoma progression

Drug intervention may prevent heart damage caused by chemotherapy

New UK SARS-CoV-2 variant circulating in US since November, says study

Combination therapy shows potential for treating lung cancer

How have new SARS-CoV-2 strains become more transmissible?

Study: NTRK fusions are far more frequently seen in pediatric tumors

New drug reduces tumor volume and pain in patients with neurofibromatosis type 1

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

Researchers investigate protein phosphatase to identify new treatments for cancer, other diseases

New taxonomic classification of non-skeletal rare congenital disorders with impact on bone physiology

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Hybrid approach reveals details about genes involved in Meier-Gorlin syndrome

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News